9804171-8

IPOS's copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 16/00, A61K 39/395 — A1

(11) International Publication Number: **WO 97/31948**

(43) International Publication Date: 4 September 1997 (04.09.97)

(21) International Application Number: PCT/EP97/01013

(22) International Filing Date: 28 February 1997 (28.02.97)

(30) Priority Data:

9604412.8	1 March 1996 (01.03.96)	GB
9617702.7	22 August 1996 (22.08.96)	GB

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(71) Applicant *(for all designated States except US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KRICEK, Franz [AT/AT]; Ulmenweg 9, A-2362 Biedermannsdorf (AT). STADLER, Beda [CH/CH]; Marienstrasse 37, CH-3005 Bern (CH).

(74) Agent: VALLET, Lucien; Novartis AG, Patents & Trademarks Dept. CH, Lichtstrasse 35, CH-4002 Basel (CH).

(54) Title: PEPTIDE IMMUNOGENS FOR VACCINATION AGAINST AND TREATMENT OF ALLERGY

(57) Abstract

Immunogenic molecules comprising (a) at least one moiety of a peptide mimicking the natural epitope on human IgE recognized by the monoclonal anti-human IgE antibody BSW17, and (b) a moiety capable of eliciting an immune response against that peptide. They are useful in, or for the preparation of, pharmaceutical compositions, particularly for the treatment of IgE-mediated diseases such as allergies and atopic dermatitis, e.g. vaccines against allergy.